Recombinant Prolidase Activates EGFR-Dependent Cell Growth in an Experimental Model of Inflammation in HaCaT Keratinocytes. Implication for Wound Healing

Magdalena Nizioł¹, Ilona Ościłowska², Weronika Baszanowska², Jerzy Palka², Roberta Besio³, Antonella Forlino³ and Wojciech Miltyk¹*

¹Department of Analysis and Bioanalysis of Medicines, Medical University of Bialystok, Bialystok, Poland, ²Department of Medicinal Chemistry, Medical University of Bialystok, Bialystok, Poland, ³Department of Molecular Medicine, University of Pavia, Pavia, Italy

This study was conducted to investigate the proliferative capacity of recombinant human prolidase (rhPEPD) in a human model of inflammation induced by IL-1β in HaCaT keratinocytes. In this report, we provide evidence that IL-1β stimulates keratinocyte proliferation, and rhPEPD significantly augmented this process through activation of epidermal growth factor receptor (EGFR) and downstream signaling proteins as phosphorylated Akt, ERK1/2, and STAT3, which are implicated in keratinocyte migration, proliferation, and epithelialization during the wound healing process. Inhibition of PEPD-dependent EGFR signaling by gefitinib supported the finding. Moreover, during activation of EGFR in the presence of IL-1β the epithelial-to-mesenchymal transition (EMT) occurred via downregulation of E-cadherin and upregulation of N-cadherin. The phenomenon was accompanied by an increase in the activity of matrix metalloproteinase-9 (MMP-9), suggesting extracellular matrix (ECM) remodeling during the inflammatory process. MMP-9 activation may result from nuclear translocation of NF-κB through IKK-mediated IkBα degradation. Interestingly, some mutated variants of PEPD (rhPEPD-G448R, rhPEPD-231delY, and rhPEPD-E412K) evoked the ability to induce EGFR-dependent HaCaT cell proliferation. To the best of our knowledge, this is the first report on the cross-talk between PEPD and IL-1β in the process of keratinocyte proliferation. The data suggest that both enzymatically active and inactive rhPEPD may activate EGFR-dependent cell growth in an experimental model of inflammation in HaCaT keratinocytes and the knowledge may be useful for further approaches for therapy of wound healing disorders.

Keywords: recombinant human prolidase, PEPD, EGFR, keratinocytes, inflammation
INTRODUCTION

Proper wound healing is a physiological process precisely regulated by numerous factors consisting of four overlapping phases: Hemostasis, inflammation, repairment, and finally, tissue remodeling. Any disturbances occurring during these steps may contribute to a delay in wound healing and form chronic ulcers and/or excessive scarring (Ellis et al., 2018). Among other organs, skin injuries are predominant and involve various cell types specializing in distinct functions e.g., keratinocytes, fibroblasts, macrophages, and endothelial cells. In the complex regulatory mechanisms of the healing process metalloproteinases (MMPs), cytokines, and enzymes are key players. Close cooperation between cells and biomolecules functionally contributes to wound contraction, re-epithelialization, and maturation processes (Yang et al., 2017).

Keratinocytes comprise about 95% of cells in the epidermal layers. As the first line cells, they encounter environmental difficulties such as pathogenic bacteria, viruses, UV radiation, and allergens leading to the production of pro-inflammatory mediators (tumor necrosis factor-α (TNF-α), interleukin (IL-1β, IL-8, etc.), and progression of chronic skin inflammation. In a response to inflammation in keratinocytes, mitogen-activated protein kinases (MAPKs) and the nuclear factor kappa beta (NF-κB) are mainly stimulated. The inflammatory signal causes translocation of transcription factors into the nucleus, such as activator protein-1 (AP-1) and NF-κB, ultimately leading to the production of a variety of proinflammatory cytokines including TNF-α, IL-1β, IL-8, and IL-6 (Nguyen and Kim, 2020). Under non-activated conditions, NF-κB occurs in the cytoplasm and is coupled to IκBα, its inhibitor protein. Upon activation by a variety of external stimuli, including bacterial lipopolysaccharide, IκBα is phosphorylated and degraded via the proteasomal degradation pathway. This event further leads to the release of NF-κB, which then is translocated to the nucleus and binds to the promoter region (κB binding site) of several genes, including iNOS and Cox-2 (Kumar et al., 2013). Similarly, MAPKs, such as ERK1/2, p38, and c-jun N-terminal kinase1/2 (JNK1/2), are components of the inflammatory signal transduction pathways that also regulate iNOS and Cox-2 expression in a variety of cells through the activation of NF-κB (Kundu and Surb, 2005).

During skin inflammation extracellular matrix (ECM) remodeling and epithelial-to-mesenchymal transition (EMT) occur as a result of various signaling pathways, e.g., Cox-2, NF-κB, MAPKs (Eberhardt et al., 2006; Lee et al., 2008; Neil et al., 2008; Räsänen and Vaheri, 2010; Hahn et al., 2016). For ECM degradation, MMPs are required, particularly MMP-2, and -9, which are activated upon external stimuli such as various cytokines and growth factors (Ranzato et al., 2017). Downregulation of E-cadherin and upregulation of N-cadherin are the typical biochemical event in EMT enabling cells to relax membrane integrity and increase cell mobility. Both activated MMPs and mobile cells functionally coordinate the wound healing process. Type-2 EMT is a part of the regeneration and restoration of physiological conditions following mechanical and inflammatory damage (Marconi et al., 2021).

Among growth factor receptors inducing cell proliferation, differentiation, growth, and migration, epidermal growth factor receptor (EGFR) exert the most potent anabolic processes (Wee and Wang, 2017). Once ligand-EGFR binding occurs, the receptor dimerizes and leads to its autophosphorylation. As a result, a cascade of downstream protein phosphorylation is induced (Yarden and Sliwkowski, 2001). The most specific protease kinases B (Akt), Ras/Raf/extracellular signal-regulated kinase (ERK), and Janus kinase (JAK)/signal transducer and activator of transcription (STAT) (Lurje and Lenz, 2009). Finally, the signal is transduced to the nucleus involving transcription factors that regulate the expression of genes coding proteins responsible for cell growth, differentiation, and metabolism (Labat-Robert and Robert, 2000). Recently, a new potent EGFR ligand, proline (PEPD) has been identified (Yang et al., 2013). It is an enzyme biologically active both intra- and extracellularly. In the cytoplasm, it acts as an enzyme [EC.3.4.13.9] by cleaving C-terminal proline or hydroxyproline-containing imidodipeptides (Jackson et al., 1975; Yaron and Naider, 1993) and thus supplying proline for protein biosynthesis, particularly collagen. Additionally, this enzyme regulates the cellular growth-promoting signaling at transcription (e.g. NF-κB) as well as post-transcriptional [e.g., hypoxia-inducible factor 1 alpha (HIF-1α)] level (Kouba et al., 1999; Rippe et al., 1999; Jaakkola et al., 2001; Surazynski et al., 2008). In the extracellular space, PEPD binds to EGFR and contributes to cell proliferation (Yang et al., 2013). Since PEPD can upregulate anabolic processes PEPD expression and enzyme activity may play a key role in tissue regeneration processes. Recently, it has been established that prolidase stimulates proliferation and migration of keratinocytes via EGFR (PI3K/Akt/mTOR axis) in an experimental model of wound healing (Misiura et al., 2020).

Human immortalized keratinocytes (HaCaT cells) maintain full epidermal differentiation capacity (Boukamp et al., 1988). Since neutrophils show increased expression of IL-1β that promotes proliferation of keratinocytes (Ellis et al., 2018), the administration of IL-1β, a pro-inflammatory cytokine, was here applied as an experimental model to investigate inflammation-associated behavior in HaCaT cells. In particular, this study was focused on explaining, in an experimental model of inflammation in HaCaT keratinocytes (IL-1β treated), the effect of recombinant human PEPD (rhPEPD) on the expression of EGFR-downstream proteins, NF-κB pathway, and MMPs activity which are known to be involved in the EMT process and ECM remodeling typically observed in the inflammatory phase of skin wound healing. Moreover, mutant forms of rhPEPD (Besio et al., 2013) were also tested for the potential to induce EGFR-downstream signaling in the experimental model.

MATERIALS AND METHODS

HaCaT Cell Cultures

HaCaT cells (CLS Cell Lines Service, 300493; Eppelheim, Germany) were cultured in a DMEM cell culture medium (PanBiotech, Aidenbach, Bayern, Germany) containing 10%
fetal bovine serum (Gibco, Carlsbad, CA, United States) and 1% penicillin/streptomycin (Gibco, Carlsbad, CA, United States) in a cell incubator (37°C, 5% CO₂). The medium was replaced every 3 days until cells reached up to 80% of confluency. Cell cultures were checked for mycoplasma infection regularly using Hoechst 33258 and confocal microscopy (BD Pathway 855 Bioimager; Becton Dickson, Franklin Lakes, NJ, United States).

Production of Recombinant Human Prolidase in E. Coli Expression System

The constructs for wild-type rhPEPD and mutant forms (rhPEPD-G448R, rhPEPD-231delY, and rhPEPD-E412K) were prepared as previously described (Lupi et al., 2006a; Besio et al., 2013). E. Coli BL21 (DE3) competent cells (Thermo Fisher Scientific, Waltham, MA, United States) were transformed with the vector of rhPEPD using the heat shock method and cultured in Luria–Bertani (LB) broth medium (Bioshop, Burlington, Ontario, Canada) with the addition of 100 g/ml ampicillin (Bioshop, Burlington, Ontario, Canada) and grown at 37°C with shaking to 200 RPM for 13 h. Then, cells were centrifuged (15 min, 4500 RPM, 4°C) and resuspended in lysis buffer (300 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM imidazole, 1 mM EDTA, 10% glycerol). After centrifugation, the supernatant containing each recombinant protein expressed as a soluble form was purified twice. Firstly, it was loaded onto a HisTrap column (BioRad Laboratories, Hercules, CA, United States) with Ni-NTA affinity resin (IMAC) equilibrated with 0.1 M NiSO₄ for purification of polyhistidine-tagged proteins. The column was eluted with elution buffer (300 mM imidazole, 300 mM NaCl, 20 mM Tris-HCl pH 8.0, 20 mM imidazole, 1 mM EDTA, 10% glycerol, 1 mM TCEP). The following step of purification included the concentration of the eluted mixture to 10 ml using ultracentrifugation filters Amicon-Ultra 10 (Merck Millipore, Burlington MA, United States) and loaded onto a Superdex 200 (Pharmacia, New Jersey, NJ, United States) gel filtration column. The recombinant proteins were activated by 1 mM Mn²⁺ at 37°C for 1 h followed by dialysis against PBS for 12 h at 4°C. The concentration of each recombinant protein was determined using a Pierce™ BCA protein assay kit (Thermo Fisher Scientific, Waltham, MA, United States) according to the instructions.

HaCaT Treatment

The cells (5–8th passages) were treated with human recombinant IL-1β (10 ng/ml; Sigma Aldrich, Saint Louis, MO, United States) and human recombinant prolidase (rhPEPDWT, rhPEPD-G448R, rhPEPD-231delY, and rhPEPD-E412K) at concentrations of 10, 25, 50, 100, 250 nM for the selected time intervals (15 min, 60 min, and 24 h). For specific applications, keratinocytes were subjected to pretreatment with gefitinib (Sigma Aldrich, Saint Louis, MO, United States), an EGFR inhibitor, at the working concentration of 2 µM for 2 h before treatment with rhPEPD (1–50 nM, 15 min and 24 h) and then cell lysates were subjected to Western immunoblotting.

Cell Viability Assay

Cell viability of HaCaT cells was measured using Cell Titer Blue assay as described in the manufacturer’s protocol (Promega, Madison, WI, United States). Cells, seeded at 5 × 10⁴ cells/well in a 96-well plate, were submitted to rhPEPDWT treatment at concentrations of 10–250 nM for 24 h. Briefly, cells were incubated with a resazurin-containing solution at 37°C for 2 h. Absorbance was read on TECAN Infinite® M200 PRO (Tecan Group Ltd., Männedorf, Switzerland) at 570 and 600 nm as a reference wavelength. The results were presented as a percent of the control value.

Cell Proliferation Assay

The proliferation of HaCaT cells was evaluated using commercially available CyQUANT® Cell Proliferation Assay (Thermo Fisher Scientific, Waltham, MA, United States). HaCaT cells, seeded at 5 × 10³ cells/well in a 96-well plate, were submitted to rhPEPDWT, rhPEPD-G448R, rhPEPD-231delY, and rhPEPD-E412K treatment at concentrations of 10–250 nM for 24 h. After incubation, cells were rinsed twice with PBS (pH 7.4) and frozen at −80°C until analysis. Before analysis, samples were thawed at room temperature (RT), and 200 µL of the CyQUANT® GR dye/cell-lysis buffer–containing mixture was added to each well and incubated for 5 min at RT. The plate was protected from light. Fluorescence was read on Victor X4 Multilabel Reader (PerkinElmer, Waltham, MA, United States) at 480 and 520 nm as excitation and emission wavelengths, respectively. The results were presented as the percent of the control value.

Cell Cycle Analysis

HaCaT cells (seeded on 6-well plates at 2 × 10⁵ cells/well) were treated with 50 nM of rhPEPDWT, rhPEPD-G448R, rhPEPD-231delY, and rhPEPD-E412K for 24 h. After incubation, cells were subjected to the protocol as published previously (Misiura et al., 2021b). Ethanol-fixed cells were analyzed using an image cytometer NC-3000 (ChemoMetec, Allerod, Denmark).

Cell Migration Assay

Confluent HaCaT cells, seeded at the density of 2 × 10⁵ cells/well at 6-well plate, were scratched with a sterile 200 µL pipette tip, rinsed with PBS, and incubated with 25 nM of rhPEPD for 24 h. The gap area was monitored using an inverted optical microscope (40x; Nikon; Minato, Tokyo, Japan).

Preparation of Lysates

The cells were seeded at the density of 2 × 10⁶ cells/plate and cultured with rhPEPDWT, rhPEPD-G448R, rhPEPD-231delY, and rhPEPD-E412K for 30 min and 24 h. Cells were rinsed twice with cold PBS (pH 7.4) and harvested with RIPA lysis buffer (Thermo Fisher Scientific, Waltham, MA, United States) containing protease inhibitor (cOmplete™ Protease Inhibitor Cocktail, Roche, Basel, Switzerland), phosphatase inhibitor cocktail (PhosSTOP, Roche, Basel, Switzerland) and viscosol (A&A Biotechnology, Gdańsk, Poland). Then, lysates were incubated on ice for 10 min and sonicated 3 times (15 s on and 5 s off) and centrifuged (4°C, 10 min, 12,000 × g). The
supernatant was aliquoted in 200 µL strip tubes and frozen at −80°C until protein analysis. The Pierce BCA assay kit (Thermo Fisher Scientific, Waltham, MA, United States) was employed for the quantification of protein concentration.

**Western Immunoblotting**

For Western immunoblotting, equal amounts (15 µg/lane) of proteins were diluted in RIPA lysis buffer (Thermo Fisher Scientific, Waltham, MA, United States) and mixed with Laemmli buffer (120 mM Tris·HCl, 20% glycerol, 0.4% SDS, and 0.02% bromophenol blue, pH 6.8) containing fresh 5% β-mercaptoethanol (Sigma Aldrich, Saint Louis, MO, United States). The samples were denatured at 99°C for 7 min. The proteins were separated on 10% SDS-PAGE gels and then blotted onto polyvinylidene difluoride (PVDF; BioRad Laboratories, Hercules, CA, United States) membranes. The membranes were blocked with either 5% non-fat dried milk (Santa Cruz Biotechnology, Dallas, TX, United States) or BSA (Sigma Aldrich, Saint Louis, MO, United States) in TBS-T (20 mM Tris, 150 mM NaCl, 0.1% Tween-20, pH 7.6) for 1 h at room temperature with agitation. The membranes were incubated with primary antibodies (listed below) overnight at 4°C, followed by incubation with alkaline phosphatase-linked goat antirabbit or antimouse antibodies for 1 h at RT. The membranes were washed three times in TBS-T for 5 min. The bands were visualized using 1-Step™ NBT/BCIP Substrate Solution (Thermo Fisher Scientific, Waltham, MA, United States) and their intensities were semiquantitatively measured with ImageJ software (https://imagej.nih.gov/ij/). All experiments were run in triplicates.

**Antibodies**

The membranes were incubated with the following primary antibodies purchased from Cell Signaling Technology (Danvers, MA, United States): Akt Rabbit mAb (1:2000), Cyclin D Rabbit mAb (1:1000), E-Cadherin Rabbit mAb (1:1000), EGFR Receptor Rabbit mAb (1:1000), GAPDH Rabbit mAb (1:1000), HIF-1α Rabbit mAb (1:1000), IKKα Mouse mAb (1:1000), IKKβ Rabbit mAb (1:1000), IkBα Rabbit mAb (1:1000), Lamin A/C Mouse mAb (1:1000), N-Cadherin Rabbit mAb (1:1000), NF-κB p65 Rabbit Antibody (1:1000), p44/42 MAPK (ERK1/2) Rabbit mAb (1:1000), PCNA Rabbit mAb (1:1000), phospho-Akt (Ser473) Rabbit mAb (1:2000), phospho-EGF Receptor (Tyr1068) Rabbit mAb (1:1000), phospho-IKKα/β (Ser176/180) Rabbit mAb (1:1000), phospho-IkBα (Ser32) Rabbit mAb (1:1000), phospho-NF-κB p65 (Ser536) Rabbit mAb (1:1000), phospho-p44/42 MAPK (Thr202/Tyr204) Rabbit mAb (1:1000), phospho-STAT3 (Tyr705) Rabbit Ab (1:1000), Stat3 Rabbit mAb (1:1000), Cox2 Rabbit mAb (1:1000), TGF-β Receptor I Rabbit Antibody (1:1000), Thymidine Kinase 1 Rabbit mAb (1:1000). Secondary alkaline phosphatase-conjugated antimouse or antirabbit antibodies diluted 1:10,000 were from Sigma Aldrich (Saint Louis, MO, United States).

**Gelatin Zymography Assay**

The activities of MMP-2 and -9 in the medium released from the cells (seeded at the density of 2 × 10⁶ cells/plate) were measured via a gelatin zymography protease assay as published by Wechselberger et al. (Wechselberger et al., 2019). After treatment, 5 ml of media were collected and concentrated using Vivaproductions Inc., Littleton, MA, United States). Protein concentration was measured using the Pierce BCA assay kit (Thermo Fisher Scientific, Waltham, MA, United States). 20 µg/lane was loaded onto 1 mg/ml gelatin-10% SDS-PAGE gels. Following electrophoresis, the gels were washed with gelatinase renaturation buffer and subsequently incubated in the gelatinase reaction buffer at 37°C for 18 h. The gels were stained with the Coomassie staining method. The relative changes in the MMP-2 and -9 activities were scanned.

**Statistical Analysis**

All experiments were carried out at least three replicates and the experiments were repeated at least three times. Data are shown as a mean ± standard deviation (SD). For statistical calculations, a one-way analysis of variance (ANOVA) with Dunnett’s correction and t-test were used. Statistical analysis was performed using GraphPad Prism 5.01 (GraphPad Software, San Diego, United States). Statistically significant differences were marked as *, **, *** p < 0.05, ***, **** p < 0.01, ****, **** p < 0.001 and **** p < 0.0001; indicates * vs. control (0 nM of PEPD, without IL-1β) cells, ** vs. control (0 nM of PEPD, with IL-1β) cells, *** significance between groups treated with or without IL-1β.

**RESULTS**

**rhPEPDWT Augments IL-1β-Stimulated Cell Proliferation and Cell Cycle Progression in HaCaT Keratinocytes**

The effect of human recombinant wild-type PEPD (rhPEPDWT) on HaCaT cell viability and proliferation was measured by testing the mitochondrial activity and by quantifying DNA content, respectively. It was found that rhPEPDWT at studied concentrations did not affect cell viability or cell proliferation of HaCaT cells (Figures 1A,B). However, in the presence of IL-1β, rhPEPDWT slightly improved cell viability (at concentrations of 10−50 nM) and moderately induced cell proliferation (especially at concentrations of 10−25 nM) of HaCaT cells (Figures 1A,B).

IL-1β and rhPEPDWT treatment contributed to a significant decrease in the percentage of cells in the G1 phase (growth) and increased the percentage of cells in the G2/M phase (mitosis), compared to control (Figures 1C,D).

It has been considered whether cell-cycle regulatory proteins may represent the underlying mechanism of rhPEPDWT-dependent action on cell proliferation. Cyclin D controls G1/S-phase transition and subsequently cell proliferation (Montalto and De Amicis, 2020). Thymidine kinase 1 is responsible for deoxythymidine triphosphate (dTTP) synthesis which is required for DNA biosynthesis
Proliferating Cell Nuclear Antigen (PCNA) participates in the critical step of DNA replication and replication-associated process, namely translation synthesis, error-free damage bypass, break-induced replication, mismatch repair, and chromatin assembly (Boehm et al., 2016). Western immunoblotting analysis showed that the expression of cyclin D, thymidine kinase 1, and PCNA were increased in PEPD- and IL-1β-stimulated HaCaT cells (Figure 1E). It suggests that in the presence of IL-1β, PEPD stimulates the proliferation of HaCaT cells via upregulation of the expression of cell-cycle regulatory proteins.
rhPEPD<sup>WT</sup> Enhances the IL-1β-Induced EGFR-Downstream Signaling Pathway in HaCaT Cells

The effect of rhPEPD<sup>WT</sup> combined with IL-1β on EGFR-downstream signaling pathways in HaCaT cells was evaluated by Western immunoblot analysis. Signal transduction is mediated by protein phosphorylation leading to activation or deactivation of many enzymes (kinases and phosphatases) and receptors (Ardito et al., 2017). EGFR-downstream signaling pathway involves Akt, ERK1/2, and STAT3. It was found that rhPEPD<sup>WT</sup> (10–100 nM) in the presence of IL-1β (10 ng/ml) increased the expression of all studied EGFR-downstream signaling proteins (Figure 2A). Interestingly, rhPEPD<sup>WT</sup> induced the expression of both total and phosphorylated forms. Phosphorylation of EGFR at Tyr1068 occurred after treatment with rhPEPD<sup>WT</sup> in a dose-dependent manner. The expression of p-Akt (Ser473) was significantly increased in prolidase-treated HaCaT cells in comparison to control non-treated cells. Similarly, the phosphorylation of ERK1/2 (Thr202/Tyr204) and STAT3 (Tyr705) was more pronounced in the cells cultured in the presence of prolidase and IL-1β than in non-treated cells.

These results were confirmed by an experiment showing that pharmacological blockade of EGFR abolished rhPEPD<sup>WT</sup>-dependent effects. Gefitinib (2 μM, 2 h), a specific EGFR inhibitor, was used to suppress rhPEPD<sup>WT</sup>-induced EGFR-downstream signaling (Figure 2B). The inhibitor strongly diminished the PEPD induced of EGFR, Akt, STAT3, and ERK1/2 phosphorylation (Figure 2B), indicating that in the presence of IL-1β, rhPEPD<sup>WT</sup> stimulates anabolic processes through EGFR downstream signaling pathway.

rhPEPD<sup>WT</sup> Promotes EMT via TGF-β1R and Cox-2 Pathway in IL-1β-Treated HaCaT Cells

Since rhPEPD in the presence of IL-1β induces EGFR-downstream signaling and enhances cell proliferation and possibly cell migration, it has been considered whether the mechanism underlying this process may involve EMT. Previous reports demonstrated an EGFR-dependent increase in cell mobility and changes in cellular junctions (Wilkins-Port and Higgins, 2007; Stoll et al., 2012). However, the mechanism responsible for EMT is not limited to EGFR activation. TGF-β1 receptor (TGF-β1R) mediates EMT through MAPK signaling, including ERK1/2 and p38 (Hahn et al., 2016) and Cox-2 signaling pathway (Neil et al., 2008; Räsänen and Vaheri, 2010). To examine whether EMT occurred, we evaluated the expression of the selected proteins by Western immunoblot. PEPD induced downregulation of E-cadherin and upregulation of HIF-1α, TGF-β1, R, Cox-2, and N-cadherin in the response of IL-1β,
suggesting that rhPEPDWT-dependent mechanism for EMT undergoes through TGF-β1R and Cox-2 pathway leading to increase in cell motility (Figure 3A). To support the statement on cell motility, the cell migration assay was performed. As shown in Figure 3B, the cell migration was improved upon IL-1β-treatment, however, rhPEPD remarkably augmented this process.

**rhPEPDWT Activates MMP-9 Through the NF-κB Pathway in IL-1β-Treated HaCaT Cells**

Since EMT occurred as described above, another biochemical event strictly related to this phenomenon was investigated such as the activation of matrix metalloproteinases. Using zymography, the activity of MMP-2 and -9 was evaluated in culture media. rhPEPDWT in the presence of IL-1β induced MMP-9 activity in a dose-dependent manner, while MMP-2 remained slightly activated in comparison to non-stimulated cells (Figure 3C). Several reports indicate that the NF-κB pathway is mainly involved in growth factor or cytokines-induced MMP-9 activation (Eberhardt et al., 2000; Lee et al., 2008). Therefore, the expression of the NF-κB family proteins was evaluated by Western immunoblot. Upon rhPEPDWT stimulation IκB kinases, IKKα and β, phosphorylation occurred at Ser176/180. Then, NF-κB was activated by degradation of IκBα releasing p65 subunit from the IκBα/NF-κB complex. Cytosolic IκBα was degraded and accompanied by an increase in the level of p-IκBα and p-IKKα/β (Figure 3D). These observations elucidate an increase in nuclear localization of NF-κB in HaCaT keratinocytes resulting in the rise of MMP-9 activity.
Mutated Variants of PEPD Differentially Affect IL-1β-Induced Cell Proliferation and EGFR Signaling in HaCaT Cells

As wild-type PEPD was shown to accelerate proliferation in IL-1β-induced HaCaT cells, it has been considered whether some mutated PEPD (rhPEPD-G448R, rhPEPD-231delY, and rhPEPD-E412K) would evoke an opposite effect on the process. All these variants occur naturally in patients with proline deficiency (PD) and manifested skin ulcers (Besio et al., 2013). Firstly, the effect of mutated variants of PEPD on IL-1β-induced HaCaT cell proliferation and cell cycle was studied. The physicochemical analysis of mutated variants of PEPD was described by Besio et al. (Besio et al., 2013).

Variant rhPEPD-G448R did not induce the proliferation of HaCaT cells both in the presence and absence of IL-1β (Figure 4A). However, rhPEPD-E412K and rhPEPD-231delY mutants in the presence of IL-1β increased the cell proliferation significantly, especially at 25, 50, and 100 nM concentrations, while in the absence of IL-1β only rhPEPD-E412K affected the process (Figures 4B,C). The analysis of the cell cycle confirmed the findings. HaCaT cultured with the PEPD mutants in the absence of IL-1β did not change significantly the ratio of G2/M to G0/G1. The cells cultured with wild-type PEPD in the presence of IL-1β showed a drastic increase in the ratio, namely significantly decreased the percentage of cells in the G0/G1 phase and increased the percentage of cells in the G2/M phase, compared to control cells cultured in the absence of IL-1β (Figure 4D). However, treatment of the cells with PEPD mutants in the presence of IL-1β decreased significantly the ratio of G2/M to G0/G1 with the more pronounced effect in the case of rhPEPD-G448R, suggesting lower potency of this mutant protein to induce EGFR-dependent stimulation of cell proliferation.

As shown in Figure 5, all studied PEPD mutants in the presence of IL-1β induced phosphorylation of EGFR and some downstream signaling proteins (Akt, ERK1/2, STAT3) as detected by Western immunoblot. rhPEPD-G448R as a ligand of EGFR was able to stimulate downstream signaling proteins, however, cell cycle analysis showed that the response was weaker compared to other PEPD mutants (rhPEPD-231delY and rhPEPD-E412K) that induced expression of p-Akt, p-STAT3, and p-ERK1/2. The data show that some mutated variants of PEPD in the presence of IL-1β evoke the ability to induce EGFR-dependent HaCaT cell proliferation.

DISCUSSION

To the best of our knowledge, this is the first report on the cross-talk between PEPD and IL-1β in keratinocyte proliferation, a process that could be of great importance in wound healing. Impaired wound healing is observed in numerous conditions such as acute and chronic diseases, aging, or post-surgery (Eming et al., 2014), thus understanding the complex regulatory mechanism of tissue regeneration is our interest. Based on the finding of Yang et al. (Yang et al., 2013) that PEPD is an EGFR
ligand and our recent study (Misiura et al., 2020), we hypothesized that extracellular PEPD under inflammatory conditions may remarkably contribute to cell proliferation facilitating wound repair. Therefore, this study was conducted to investigate the biological effects of PEPD on human keratinocytes in an *in vitro* model of IL-1β-induced inflammation using HaCaT immortalized human keratinocytes. We found that PEPD in the presence of IL-1β significantly augmented keratinocyte proliferation through EGFR signaling. Treatment of keratinocytes with IL-1β contributes to the hyperproliferative and migratory phenotype of the cells (Franchi et al., 2009). Indeed, it is well established that IL-1β and EGFR are over-expressed in wounded skin, particularly during the inflammatory phase (Barrientos et al., 2008; Yoshida et al., 2008). The key finding of our study is that PEPD activates EGFR-downstream signaling proteins including Akt, ERK1/2, and STAT3, which are implicated in keratinocyte migration, proliferation, and epithelialization during the inflammatory phase of the wound healing process. PEPD-induced Akt and MAPK signaling in HaCaT cells was reported previously (Misiura et al., 2020).

The finding that PEPD is the ligand of EGFR (Yang et al., 2013) was thoroughly validated. The researchers compared the affinity of EGF and PEPD to the EGFR extracellular domain and found that EGF is a more potent ligand than prolidase. However, EGF can displace PEPD from its complex with EGFR. Interestingly, PEPD and EGFR colocalize the cell membrane indicating a ligand-receptor relationship. In our study, we also addressed the question of whether EGFR-mediated observations are dependent on PEPD. Thus, we employed a pharmacological EGFR inhibitor, gefitinib. Inhibition of PEPD-dependent EGFR activation by gefitinib led to a decrease in the amount of phosphorylated and total forms of EGFR and Akt, ERK1/2, and STAT3 confirming that PEPD is a ligand of this receptor. We found that PEPD exerts cell cycle progression in keratinocytes via regulating G1, S, and G2/M phases. The entry of eukaryotic cells into mitosis is strictly regulated at several steps including cyclin D, thymidine kinase 1, PCNA, and others. Indeed they all were upregulated in response to PEPD. The data correspond to the study conducted by Kim et al. (Kim et al., 2013) who presented upregulation of cyclin D in growth factor-stimulated HaCaT cells. Thus, the activation of cyclins may influence the epidermal cells to promote the wound healing process.

However, PEPD-dependent stimulation of keratinocyte proliferation requires the participation of IL-1β. Although the
mechanism for the process is not known it has been previously suggested that EGFR and IL-1β signaling synergistically promote keratinocyte proliferation and differentiation (Johnston et al., 2011). We found that during stimulation of EGFR in the presence of IL-1β the EMT occurred, as detected by changes in the expression of EMT markers such as E-cadherin and N-cadherin. Besides the downregulation of E-cadherin and upregulation of N-cadherin, Cox-2 and TGF-β1 were significantly pronounced upon rhPEPDWT treatment. Several papers suggest that EMT is mediated through the aforementioned pathways which are consistent with our study (Neil et al., 2008; Räsanen and Vaheri, 2010; Stoll et al., 2012). The phenomenon was accompanied by an increase in the activity of MMP-9. MMPs are secreted by keratinocytes to digest ECM constituents in response to external stimuli. The activation of MMPs essential during the inflammatory and reepithelialization phases of wound healing and regulates the EMT process (Yang et al., 2017).

Moreover, we demonstrated that total NF-κB expression was drastically increased due to IL-1β treatment and gradually decreased under PEPD treatment of keratinocytes, however, NF-κB phosphorylation was remarkably high, similarly to phosphorylated forms of IkB α/β and IkBa. It is well established that inflammation activates the NF-κB and MAPK signaling processes (Solt and May, 2008). Activated NF-κB then enters the nucleus, inducing gene transcription involved in the inflammatory response. In quiescent cells, NF-κB in the cytosol is bound to its inhibitory molecule, IkBa protein. Upon stimulation, IkBa is phosphorylated by the upstream kinases, IKKa and β, which induces the ubiquitination and degradation of IkBa protein in proteasomes, subsequently leading to the phosphorylation and translocation of NF-κB into the nucleus (Chen et al., 1999). Activated NF-κB binds to specific DNA sequences and regulates the expression of its target genes. Interestingly, in the present study, we found that MMP-9 was activated suggesting the increased ability of HaCaT cells to digest surrounding ECM and migrate. The link between increased MMP-9 activity and activation of NF-κB was indicated by Eberhardt et al. (Eberhardt et al., 2000) who identified the promoter region in the MMP-9 gene containing a binding site for nuclear factor κB. Thus, in rhPEPDWT-mediated MMP-9 activation, the NF-κB pathway is involved.

Keratinocytes are the source and target for cytokines. A vast range of inflammatory mediators is expressed and secreted by keratinocytes that have multiple consequences not only for inflammatory cells through the promotion of leukocytes migration, amplification of inflammatory responses but also on keratinocytes to promote their proliferation and differentiation processes (Jiang et al., 2020). Thus, under experimental scratch conditions, while the cell membrane is disrupted, a variety of inflammatory mediators may be released from keratinocytes. The interplay between prolidase and secreted mediators of inflammation contributes to the induction of cell proliferation, growth, and migration as presented previously (Misiura et al., 2020). The current research on the effect of prolidase in IL-1β-induced inflammation supports the hypothesis that prolidase in the presence of IL-1β strengthens the proliferative and migratory capacity of keratinocytes. The molecular mechanism underlying PEPD-induced cell proliferation and growth undergoes through EGFR signaling, cell cycle progression, EMT, as well as matrix remodeling. It cannot be excluded that IL-1β stimulates the release of PEPD from keratinocytes, however, it needs further experiments supporting this hypothesis. Based on the experience, it was found that prolidase is expressed by keratinocytes, although PEPD activity is low. To date, the system for prolidase transport outside the cell remains unknown unless the cell membrane is discontinued. Under chemically-induced cell disruption PEPD concentration significantly increases (Yang et al., 2013). Another possible source of prolidase can be platelets in the bloodstream (Guszczyń et al., 2017; Misiura et al., 2021a). Platelets are essential players in the initial stage of inflammation as they carry various inflammatory mediators. Upon activation and degranulation of platelets, growth factors and prolidase-containing load is released close to the wound area. It is known that platelet-rich plasma is used in regenerative medicine facilitating the recovery from tissue injuries (Marx, 2001; Amable et al., 2013; Etulain, 2018; Emer, 2019).

So far, the functional significance of PEpd was found in PEpd deficiency (PD, OMIM 170100). This is a rare autosomal recessive disorder characterized by massive imidodipeptiduria, skin lesions, and elevated proline-containing dipeptides in plasma (Scrivere, 1964; Goodman et al., 1968; Powell and Maniscalco, 1976; Umemura, 1978; Isemura et al., 1979; Freij et al., 1984; Pierard et al., 1984). Currently, it is believed that mutations in the PEpd gene explain the molecular basis for PD, and several mutated alleles were found (Endo and Matsuda, 1991; Ledoux et al., 1996; Lupi et al., 2006b). However, it is difficult to indicate the exact cause for PD since clinical phenotype is not always related to genotype (Lupi et al., 2008). To date, PD is diagnosed by low or a lack of PEpd activity, however, the clinical outcome may be due to deprivation of extracellular function of PEpd. This hypothesis would be confirmed since PD therapy was unsuccessful with the application of proline or proline-convertible amino acids (Kitchener and Grunden, 2012). As PD remains incurable, we sought to explore the effect of the selected mutated variants of PEpd (rhPEPD-G448R, rhPEPD-231delY, and rhPEPD-E412K) on EGFR-downstream proteins under IL-1β-induced inflammation. Interestingly, EGFR-downstream protein analysis showed that some mutated variants of PEpd (rhPEPD-231delY and rhPEPD-E412K) were able to activate EGFR-dependent intracellular signal and induce HaCaT cell proliferation stronger than another mutated variant (rhPEPD-G448R). The possible explanation for weaker ligand properties of rhPEPD-G448R could be its secondary structure compositions (rhPEPD-G448R). However, the system for prolidase transport outside the cell remains unknown unless the cell membrane is discontinued. Under chemically-induced cell disruption PEPD concentration significantly increases (Yang et al., 2013). Another possible source of prolidase can be platelets in the bloodstream (Guszczyń et al., 2017; Misiura et al., 2021a). Platelets are essential players in the initial stage of inflammation as they carry various inflammatory mediators. Upon activation and degranulation of platelets, growth factors and prolidase-containing load is released close to the wound area. It is known that platelet-rich plasma is used in regenerative medicine facilitating the recovery from tissue injuries (Marx, 2001; Amable et al., 2013; Etulain, 2018; Emer, 2019).
characterized by an increase in random coil while the contribution of α-helices and β-sheets were decreased. Given together, it is probable that the EGFR ligand properties of the studied rhPEPD correspond to their architecture. Accordingly, Yang et al. (Yang et al., 2015; 2016) performed research with a mutated form of prolidase (rhPEPD-G278D) and observed that even inactive enzyme acts as a functional ligand. Based on these results a question arise of whether symptoms in PD patients result from low or lack of intracellular activity or lack of extracellular PEPD function. Data presented in this report suggest that the extracellular function of PEPD is of great importance in EGFR-dependent stimulation of keratinocyte proliferation in conditions of experimental inflammation. Our study suggests that cell proliferation and the intracellular responses upon activation of EGFR by PEPD mutants are weaker than in the case of PEPD WT. It seems to match the clinical outcomes as PD patients manifest a wide range of symptoms (Besio et al., 2013). It suggests that not only PEPD activity but an extracellular function of PEPD may be involved in the mechanism underlying prolidase deficiency. Similar effects were reported for a keratinocyte growth factor (KGF), another ligand of EGFR inducing cell proliferation as a mechanism for alveolar epithelial repair (Atabai et al., 2002). Interestingly, IL-1 that was found in elevated concentrations in the pulmonary edema fluid of patients with acute lung injury, promoted in vitro alveolar epithelial repair through an EGFR pathway (Geiser et al., 2000). However, the repair effect was independent of its mitogenic effect. It has been suggested that the augmented rate of epithelial repair in these conditions is the result of enhanced cell spreading and migration, but not cell proliferation (Atabai et al., 2002). Whether wild-type PEPD, as well as mutated variants of PEPD, could stimulate similar mitogenic independent effects on the wound healing process requires to be explored.

Thus, the biological activity of PEPD and its genetic variants is of emerging research interest. So far, it is known that PEPD act as a regulator of p53 function, affects interferon-α/β receptor maturation, and is a ligand of EGFR and epidermal growth factor receptor 2 (HER2) (Misiura and Miltyk, 2020). Our results demonstrate for the first time that PEPD activates EGFR-dependent cell growth in an experimental model of inflammation in HaCaT keratinocytes and the knowledge may be useful for further approaches for therapy of wound healing disorders.

CONCLUSION

The data presented in this report suggest that human recombinant wild-type rhPEPD, as well as some mutated variants of PEPD, activate, through EGFR-dependent signaling, cell proliferation, and ECM remodeling in an experimental model of inflammation in HaCaT keratinocytes. The data suggest that both enzymatically active and inactive rhPEPD may modulate, even if with different intensity, EGFR signaling and the knowledge may be useful for further approaches for therapy of wound healing disorders.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

Conceptualization, MN, IO, JP and WM; methodology, MN, RB and IO; investigation, MN, RB and WB; data curation, MN, WB, and IO; writing—original draft preparation, MN; writing—review and editing, JP, AF and WM; visualization, MN and IO; supervision, WM; funding acquisition, WM. All authors have read and agreed to the published version of the manuscript.

FUNDING

This research received was funded by the National Centre of Science, Poland, Grant No. 2017/25/B/NZ7/02650. The publication was written during doctoral studies under project No. POWR.03.02.00-00-I051/16 co-funded from the European Union funds, Operational Programme Knowledge Education Development for the years 2014–2020.

ACKNOWLEDGMENTS

The assistance in the purification of recombinant human prolidase provided by Justyna Czyrko-Horczak was greatly appreciated.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmolb.2022.876348/full#supplementary-material

REFERENCES

Amable, P. R., Carias, R. B. V., Teixeira, M. V. T., da Cruz Pacheco, I., Corrêa do Amaral, R. J. F., Granjeiro, J. M., et al. (2013). Platelet-rich Plasma Preparation for Regenerative Medicine: Optimization and Quantification of Cytokines and Growth Factors. Stem Cell Res Ther 4 (3), 67. doi:10.1186/scrt218

Ardito, F., Giuliani, M., Perrone, D., Troiano, G., and Muzio, L. L. (2017). The Crucial Role of Protein Phosphorylation in Cell Signaling and its Use as Targeted Therapy (Review). Int. J. Mol. Med. 40 (2), 271–280. doi:10.3892/ijmm.2017.3036

Nizioł et al.  rhPEPD in IL-induced Inflammation
Misiura, M., Baszanowska, W., Ościłowska, I., Palka, J., and Miltyk, W. (2020). Prolidase Stimulates Proliferation and Migration through Activation of the PI3K/Akt/mTOR Signaling Pathway in Human Keratinocytes. Int. J. Mol. Sci. 21 (23), 9243. doi:10.3390/ijms21239243

Misiura, M., Guszczyn, T., Oscilowska, I., Baszanowska, W., Palka, J., and Miltyk, W. (2021a). Platelet-Rich Plasma Promotes the Proliferation of Human Keratinocytes via a Progression of the Cell Cycle. A Role of Prolidase. Int. J. Mol. Sci. 22 (2), 936. doi:10.3390/ijms22020936

Misiura, M., Ościłowska, I., Bielawska, K., Palka, J., and Miltyk, W. (2021b). PRODH/POX-Dependent Celenocib-Induced Apoptosis in MCF-7 Breast Cancer. Pharmaceuticals (Basel) 14 (9), 874. doi:10.3390/ph14090874

Montalto, F. I., and De Amicis, F. (2020). Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma. Cells 9 (12), 874. doi:10.3390/cells9122648

Munch-Petersen, B. (2010). Enzymatic Regulation of Cytosolic Thymidine Kinase 1 and Mitochondrial Thymidine Kinase 2: a Mini Review. Nucleosides Nucleotides Nucleic Acids 29 (4-6), 363–369. doi:10.1080/15257771003729591

Neil, J. R., Johnson, K. M., Nemenoff, R. A., and Schiemann, W. P. (2008). Cox-2 Inactivates Smad Signaling and Enhances EMT Stimulated by TGF-β through a PGE2-dependent Mechanisms. Carcinogenesis 29 (11), 2227–2235. doi:10.1093/carcin/bgn202

Nguyen, A. T., and Kim, K. Y. (2020). Inhibition of Proinflammatory Cytokines in Cutibacterium Acnes-Induced Inflammation in HaCat Cells by Using Buddleja Davidiui Aqueous Extract. Int. J. Inflamm. 2020, 8063289. doi:10.1155/2020/8063289

Pierard, G. H., Pierard, G. E., Cornil, F., and Lapière, C. M. (1984). Pathogenesis of Ulercations in Deficiency of Prolidase. The Role of Angiopathy and of Deposits of Amyloid. The Am. J. Dermatopathol. 6 (5), 491–498. doi:10.1097/00000372-198410000-00013

Powell, G. F., and Maniscalco, R. M. (1976). Bound Hydroxyproline Excretion Following Gelatin Loading in Prolidase Deficiency. Metabolism 25 (5), 503–508. doi:10.1016/0026-0495(76)90003-2

Räsänen, K., and Vaheri, A. (2010). TGF-beta Causes Epithelial-Mesenchymal Transition in HaCat Derivatives, but Induces Expression of COX-2 and Migration Only in Benign, Not in Malignant Keratinocytes. J. Dermatol. Sci. 58 (2), 97–104. doi:10.1016/j.jdermsci.2010.03.002

Ranzato, E., Martinotti, S., Volante, A., Tava, A., Masini, M. A., and Burlando, B. (2017). The Major Boswellia Serrata Active 3-Acetyl-11-Keto-β-Boswellic Acid Strengthens Interleukin-1α Uregulation of Matrix Metalloproteinase-9 via JNK MAP Kinase Activation. Phytotherapy Research 31 (6), 762–766. doi:10.1002/ptr.5985

Rippe, R. A., Schrum, L. W., Stefanovic, B., Solis-Herruzo, J. A., and Brenner, D. A. (1999). NF-kappaB Inhibits Expression of the alpha1(I) Collagen Gene. DNA Cell Biol. 18 (10), 751–761. doi:10.1089/104454999314890

Scriber, C. R. (1964). Glycyrl-Proline in Urine of Humans with Bone Disease. Can. J. Physiol. Pharmacol. 42, 357–364. doi:10.1139/y64-043

Solt, L. A., and May, M. J. (2008). The IkappaB Kinase Complex: Master Regulator of NF-kappaB Signaling. Immunol. Rev. 217 (1-3), 3–18. doi:10.1111/j.1600-065X.2008.00825-1

Stoll, S. W., Rittie, L., Johnson, J. L., and Elder, J. T. (2012). Heparin-binding EGF-like Growth Factor Promotes Epithelial-Mesenchymal Transition in Human Keratinocytes. J. Invest. Dermatol. 132 (9), 2148–2157. doi:10.1038/jid.2012.78

Surzynska, A., Donald, S. P., Cooper, S. K., Whiteside, M. A., Salnikow, K., Liu, Y., et al. (2008). Extracellular Matrix and HIF-1 Signaling: the Role of Prolidase. Int. J. Cancer 122 (6), 1435–1440. doi:10.1002/ijc.23263

Umemura, S. (1978). Studies on a Patient with Inimodipeptiduria. II. Lack of Prolidase Activity in Blood Cells. Physiol. Chem. Phys. 10 (3), 279–283.

Wechselberger, C., Doppler, C., and Bernhard, D. (2019). An Inexpensive Staining Alternative for Gelatin Zymography Gels. Methods Protoc. 2 (3), doi:10.3390/mps2030061

Wee, P., and Wang, Z. (2017). Epidermal Growth Factor Receptor Cell Proliferation Signaling Pathways. Cancers (Basel) 9 (5), 92. doi:10.3390/cancers9050052

Wilkins-Port, C. E., and Higgins, P. J. (2007). Regulation of Extracellular Matrix Remodeling Following Transforming Growth Factor-Beta1/epidermal Growth Factor-Stimulated Epithelial-Mesenchymal Transition in Human Premalignant Keratinocytes. Cells Tissues Organs 185 (1-3), 116–122. doi:10.1159/000101312

Yang, L., Li, Y., Ding, Y., Chou, K.-S., Kazim, A. L., and Zhang, Y. (2013). Prolidase Directly Binds and Activates Epidermal Growth Factor Receptor and Stimulates Downstream Signaling. J. Biol. Chem. 288 (4), 2365–2375. doi:10.1074/jbc.m112.429159

Yang, L., Li, Y., Bhattacharya, A., and Zhang, Y. (2015). Inhibition of ERBB2-Overexpressing Tumors by Recombinant Human Prolidase and its Enzymatically Inactive Mutant. ElBioMedicine 2 (5), 396–405. doi:10.1016/j.elbion.2015.03.016

Yang, L., Li, Y., Bhattacharya, A., and Zhang, Y. (2016). Dual Inhibition of ErbB1 and ErbB2 in Cancer by Recombinant Human Prolidase Mutant hPEPD-G278D. Oncotarget 7 (27), 42340–42352. doi:10.18632/oncotarget.9851

Yang, H.-L., Tsai, Y.-C., Koriya, M., Chang, C.-T., and Hseu, Y.-C. (2017). Lucidone Promotes the Cutaneous Wound Healing Process via Activation of the PI3 K/AKT, Wnt/β-Catenin and NF-kB Signaling Pathways. Biochim. Biophys. Acta (Bba) - Mol. Cel Res. 1864 (1), 151–168. doi:10.1016/j.bbamer.2016.10.021

Yarden, Y., and Slwikowski, M. X. (2001). Untangling the ErbB Signalling Network. Nat. Rev. Mol. Cell Biol 2 (2), 127–137. doi:10.1038/35052073

Yaron, A., Naider, F., and Scharpe, S. (1993). Proline-dependent Structural and Biological Properties of Peptides and Proteins. Crit. Rev. Biochem. Mol. Biol. 28 (1), 31–81. doi:10.3109/10409293908125752

Yoshida, A., Kanno, H., Watabe, D., Akasaka, T., and Sawai, T. (2008). The Role of Heparin-Binding EGF-like Growth Factor and Amphiregulin in the Epidermal Proliferation of Priossi in Cooperation with TNFα. Arch. Dermatol. Res. 300 (1), 37–45. doi:10.1007/s00403-007-0809-y

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Niżoł, Ościłowska, Baszanowska, Palka, Besio, Forlino and Miltyk. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.